The Government says it has secured an agreement for 30 million doses of a vaccine being developed - and currently at phase two trials - by BioNTech and German firm Pfizer.

There has also been an in-principle deal done for 60 million doses of a vaccine that is being developed by France's Valneva.

The figure of 90 million is in addition to the 100 million doses of vaccine that are being developed by Oxford University in partnership with AstraZeneca.

But the head of the UK's vaccine taskforce has insisted that the Government is "not pursuing a strategy of vaccine nationalism".

Kate Bingham said the UK's goal was "to find vaccines for the UK, but also to ensure that any successful vaccine is distributed across the globe, so that anybody who is at risk of infection is vaccinated".

In other vaccine news, long-awaited data has shown that the vaccine being developed by the University of Oxford and AstraZeneca did not prompt any serious side effects and elicited both an antibody and T-cell immune response.

The results, published in the Lancet, are from a Phase I/II trial carried out in 1,077 healthy volunteers. Professor Sarah Gilbert, lead researcher of the vaccine development programme, has said the "early results hold promise".

Read the latest on this story here: https://www.telegraph.co.uk/politics/2020/07/20/uk-lockdown-coronavirus-boris-johnson-news-update/?WT.mc_id=tmg_youtube_offsite_televideo-youtubevideo_July20Raab&utm_source=tmgoff&utm_medium=tmg_youtube&utm_content=offsite_televideo&utm_campaign=tmg_youtube_offsite_televideo-youtubevideo_July20Raab

Get the latest headlines: https://www.telegraph.co.uk/

Telegraph.co.uk and YouTube.com/TelegraphTV are websites of The Telegraph, the UK's best-selling quality daily newspaper providing news and analysis on UK and world events, business, sport, lifestyle and culture.